Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 19/20 | 0.54 |
| ▸ | HTR2A | P28223 | 15/20 | 0.54 |
| ▸ | HTR1A | P08908 | 11/20 | 0.54 |
| ▸ | DRD4 | P21917 | 4/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | DRD1 | P21728 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19018842 | 0.99 | DRD2 (0.54) | DRD2HTR2AHTR1ADRD4DRD3 | |
| SCHEMBL20058518 | 0.93 | DRD2 (0.51) | DRD2HTR2AHTR1ADRD4DRD3 | |
| SCHEMBL20058516 | 0.92 | DRD2 (0.46) | DRD2HTR2AHTR1ADRD4DRD3 | |
| SCHEMBL20058850 | 0.92 | DRD2 (0.46) | DRD2HTR2AHTR1ADRD4DRD3 | |
| SCHEMBL19018846 | 0.92 | DRD2 (0.48) | DRD2HTR2AHTR1ADRD4DRD3 | |
| SCHEMBL20058810 | 0.92 | DRD2 (0.47) | DRD2HTR2AHTR1ADRD4DRD3 | |
| SCHEMBL23721754 | 0.91 | DRD2 (0.54) | DRD2HTR2AHTR1ADRD4DRD3 | |
| SCHEMBL22417472 | 0.91 | DRD2 (0.53) | DRD2HTR2AHTR1ADRD4DRD3 | |
| SCHEMBL24654551 | 0.90 | DRD2 (0.53) | DRD2HTR2AHTR1ADRD4DRD3 | |
| SCHEMBL20058506 | 0.90 | DRD2 (0.48) | DRD2HTR2AHTR1ADRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4124616-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | Alkermes Pharma Ireland Limited (IE) | 2023-02-01 | — | — | EP | disclosed |
| EP-3309151-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | Alkermes Pharma Ireland Limited (IE) | 2018-04-18 | — | — | EP | disclosed |
| EP-2445502-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES PHARMA IRELAND LTD (IE) | 2017-06-21 | — | — | EP | disclosed |